Note: This story was updated Dec. 17, 2025, to correct that the infiltrations were done in the parotid glands, not the parathyroid. A minimally invasive treatment that involves irrigating the major salivary glands with corticosteroids, a type of anti-inflammatory medication, significantly reduced both objective and subjective measures of dry mouth…
News
Four genes involved in a form of cell death called pyroptosis are highly active in people with Sjögren’s disease and may serve as disease biomarkers or therapeutic targets, a study reports. By examining the activity of each of the genes — PECAM1, IFI16, AIM2, and MPEG1 —the researchers…
A new artificial intelligence (AI) tool has demonstrated the ability to significantly enhance the diagnosis of Sjögren’s disease by rapidly and accurately analyzing tissue samples, according to a multicenter European study. The AI system achieved an accuracy of more than 87% in classifying the focus score, which is the…
The severity of fatigue experienced by people with Sjögren’s disease affects their pain severity, and also has an impact on the effect of external factors, such as weather changes and loud noises, that can amplify a patient’s pain. That’s according to the findings of a single-center study in Italy,…
Two global Phase 3 clinical trials are now testing dazodalibep, Amgen’s experimental therapy for Sjögren’s disease, in two groups of adults. One of the studies is still recruiting participants. One of the trials, called HZNP-DAZ-301 (NCT06104124), has completed enrollment of 651 people with moderate-to-severe systemic (body-wide) Sjögren’s…
People with Sjögren’s disease who received the experimental therapy ianalumab (VAY736) in Phase 3 clinical trials reported greater reductions in disease activity than those given a placebo within two months of starting treatment. That’s according to new data ianalumab’s developer, Novartis, shared at the American College of Rheumatology…
Sjögren’s disease patients found significant relief from debilitating symptoms like dryness, pain, and fatigue after treatment with Johnson & Johnson’s investigational antibody, nipocalimab, in a Phase 2 clinical trial. Full results from the study, dubbed DAHLIAS (NCT04969812), confirmed that nipocalimab treatment, compared to a placebo, not only…
An experimental therapy from Ouro Medicines is being tested in a Phase 1b clinical trial on people who have Sjögren’s disease or idiopathic inflammatory myopathy (IMM), another autoimmune condition. “This study reflects Ouro’s strategy of expanding OM336 development to additional immune-mediated diseases where an ‘immune reset’ approach would…
The investigational therapy telitacicept leads to significant and clinically meaningful reductions in disease activity and patient-reported symptoms among adults with primary Sjögren’s disease, according to new data from a Phase 3 clinical trial conducted in China. The findings — consistent with Phase 2 trial data — were…
A machine learning tool that can analyze certain molecules in stool samples may help to better diagnose primary Sjögren’s disease, according to a new study from researchers in China. The team found that their novel model, using fecal samples, could distinguish primary Sjögren’s patients from healthy individuals with an…
Recent Posts
- Sjögren’s disease may increase risk of certain digestive cancers: Korean study
- Sjögren’s patients face ‘invisible’ symptoms, lack of understanding
- Sjögren’s protein score may help measure salivary gland inflammation
- AI tools find 12 biomarkers that may speed a Sjögren’s diagnosis
- A closer look at Sjögren’s disease: How Johnson & Johnson is driving patient-informed research
- Investment funds development of ‘Goldilocks’ treatment for dry eyes
- AI system may accurately diagnose Sjögren’s using routine lab tests: Study
- FDA grants breakthrough status to experimental Sjögren’s drug ianalumab
- New study uses artificial intelligence to uncover Sjögren’s disease subtypes
- Blood molecule may offer new way to detect and track Sjögren’s disease